Recruiting
A Comparative Effectiveness Study of Positive Airway Pressure (PAP) Therapy, Dental Device, and Atomoxetine-Oxybutynin for Treatment of Obstructive Sleep Apnea in Adults
NCT07679282· Phase 4· Sairam Parthasarathy· Source
Contact: Nayeli Lopez
Recruiting
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
NCT07214376· Pulnovo Medical, Inc.· Source
Contact: Sorajja
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
NCT07558265· Ohio State University· Source
Contact: Jarrod Mosier, MD
Recruiting
Apixaban Versus Warfarin for Left Ventricular Thrombus
NCT07709780· Phase 3· University of Arizona· Source
Contact: Tushar Acharya, MD, MPH (principal investigator)
Recruiting
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
NCT07195734· Phase 2· National Cancer Institute (NCI)· Source
Contact: Ricklie A. Julian (principal investigator)
Enrolling by invitation
Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
NCT06773936· Phase 2· SWOG Cancer Research Network· Source
Recruiting
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
NCT07198074· Phase 3· National Cancer Institute (NCI)· Source
Contact: Marina D. Miller (principal investigator)
Recruiting
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
NCT06931340· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Edward P. Gelmann (principal investigator)
Recruiting
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
NCT06649812· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
NCT06724237· Phase 3· Eastern Cooperative Oncology Group· Source
Contact: Muhammad Husnain (principal investigator)
Recruiting
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
NCT06770582· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT06124157· Phase 2· National Cancer Institute (NCI)· Source
Contact: Monica M. Davini (principal investigator)
Recruiting
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
NCT06616584· Phase 2/3· SWOG Cancer Research Network· Source
Contact: Linda L. Garland (principal investigator)
Recruiting
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
NCT06672146· Phase 2· National Cancer Institute (NCI)· Source
Contact: Sharad Khurana (principal investigator)
Recruiting
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
NCT06401330· Phase 3· Children's Oncology Group· Source
Contact: Monica M. Davini (principal investigator)
Recruiting
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
NCT06661720· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Edward P. Gelmann (principal investigator)
Recruiting
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
NCT06513962· Phase 3· Children's Oncology Group· Source
Contact: Monica M. Davini (principal investigator)
Recruiting
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
NCT06632977· Phase 2· Alliance for Clinical Trials in Oncology· Source
Contact: Edward P. Gelmann (principal investigator)
Active, not recruiting
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455· Phase 3· NRG Oncology· Source
Recruiting
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
NCT06337318· Phase 3· National Cancer Institute (NCI)· Source
Contact: Krishna Rekha Moturi (principal investigator)
Recruiting
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
NCT06317649· Phase 2· National Cancer Institute (NCI)· Source
Contact: Sharad Khurana (principal investigator)
Recruiting
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
NCT05554406· Phase 2· National Cancer Institute (NCI)· Source
Contact: Sharad Khurana (principal investigator)
Recruiting
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
NCT05554393· Phase 2· National Cancer Institute (NCI)· Source
Contact: Sharad Khurana (principal investigator)
Recruiting
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
NCT06422806· Phase 3· National Cancer Institute (NCI)· Source
Contact: Anna Roshal (principal investigator)
Recruiting
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
NCT06022939· Phase 3· SWOG Cancer Research Network· Source
Contact: Muhammad Husnain (principal investigator)
Recruiting
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
NCT05564390· Phase 2· National Cancer Institute (NCI)· Source
Contact: Sharad Khurana (principal investigator)
Recruiting
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NCT06172296· Phase 3· National Cancer Institute (NCI)· Source
Contact: Monica M. Davini (principal investigator)
Recruiting
Strategy for Improving Stroke Treatment Response
NCT05948566· Phase 2· Translational Sciences, Inc.· Source
Contact: Firas Kaddouh, MD, MHS
Recruiting
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241· Phase 2/3· National Cancer Institute (NCI)· Source
Contact: Edward P. Gelmann (principal investigator)
Recruiting
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
NCT05773274· Phase 2· National Cancer Institute (NCI)· Source
Contact: Rachna T. Shroff (principal investigator)
Recruiting
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
NCT05890352· Phase 2· SWOG Cancer Research Network· Source
Contact: Krishna Rekha Moturi (principal investigator)
Active, not recruiting
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
NCT05602194· Phase 3· Children's Oncology Group· Source
Recruiting
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NCT05624996· Phase 3· NRG Oncology· Source
Contact: Charles C. Hsu (principal investigator)
Recruiting
Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy
NCT05865301· Stanford University· Source
Contact: Laurel Truscott
Recruiting
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05633615· Phase 2· SWOG Cancer Research Network· Source
Contact: Muhammad Husnain (principal investigator)
Active, not recruiting
Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial
NCT05408546· Phase 2· Translational Sciences, Inc.· Source
Active, not recruiting
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
NCT05538897· Phase 1/2· National Cancer Institute (NCI)· Source
Active, not recruiting
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
NCT05633602· Phase 3· SWOG Cancer Research Network· Source
Active, not recruiting
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
NCT05256225· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
NCT05438212· Phase 3· NRG Oncology· Source
Recruiting
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169· Phase 2/3· NRG Oncology· Source
Contact: Aaron J. Scott (principal investigator)
Active, not recruiting
A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor
NCT04939597· Phase 3· Children's Oncology Group· Source
Recruiting
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
NCT05040360· Phase 2· SWOG Cancer Research Network· Source
Contact: Junaid Arshad (principal investigator)
Recruiting
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
NCT04726241· Phase 1/2· PedAL BCU, LLC· Source
Contact: Monica M. Davini (principal investigator)
Recruiting
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
NCT05235165· Phase 3· Children's Oncology Group· Source
Contact: Michelina de la Maza (principal investigator)
Recruiting
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
NCT04840602· Phase 2· National Cancer Institute (NCI)· Source
Contact: Muhammad Husnain (principal investigator)
Active, not recruiting
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin
NCT04533750· Phase 1· National Cancer Institute (NCI)· Source
Active, not recruiting
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
NCT04708418· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
NCT04759586· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
NCT04994132· Phase 3· Children's Oncology Group· Source
Showing 50 of 150.